Tyrosine

Type: Keyphrase

Name: Tyrosine

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Development of a Spontaneous Liver Disease Resembling Autoimmune Hepatitis in Mice Lacking Tyro3, Axl and Mer Receptor Tyrosine Kinases

by Nan Qi, Peipei Liu, Yue Zhang, Hui Wu, Yongmei Chen, Daishu HanAutoimmune hepatitis (AIH) is a severe type of chronic liver disease. The lack of appropriate animal models has resulted in a limited understanding regarding the etiology of AIH. Here, ... [Published Elites TV - Jun 18 2013]

Entities: Autoimmune Hepatitis, Tyrosine, Receptor

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Nutrients

Taking a birth control pill? It might be leaching nutrients from your body

Ross Pelton, author of The Pill Problem, says that his career has bridged two worlds: that of a registered pharmacist dealing with medications and that of a certified clinical nutritionist concerned with natural healing.This duality has led him to discover ... [Published Metronews - Jun 18 2013]

Entities: Nutrients, Leaching, Contraceptive Pill

First reported Jun 16 2013 - Updated Jun 17 2013 - 1 reports

AVEO Pharmaceuticals Inc

Aveo Pharma Hanging By A Thread

Aveo Pharmaceuticals (AVEO) has recently faced many setbacks related to its New Drug Application for tivozanib, a tyrosine kinase inhibitor targeted for advanced renal cell carcinoma. After receiving a negative review in the FDA Advisory Panel, the FDA ... [Published Seeking Alpha - Jun 16 2013]

Entities: tivozanib, AVEO Pharmaceuticals Inc, Kinase, Receptor

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Exelixis Inc

Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

By a News Reporter-Staff News Editor at Pharma Business Week Exelixis, Inc. (NASDAQ:EXEL) announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma (mRCC) who have ... [Published Pharmacy Choice - Jun 17 2013]

Entities: cabozantinib, renal cell carcinoma, Patient, Exelixis Inc

First reported Jun 15 2013 - Updated Jun 15 2013 - 1 reports

Patent Issued for Selected Inhibitors of Protein Tyrosine Kinase Activity

(NewsRx) -- By a News Reporter-Staff News Editor at Angiogenesis Weekly -- A patent by the inventors Raeppel, Stephane (St. Lazare, CA); Zhan, Lijie (Montreal, CA); Claridge, Stephen William (Montreal, CA); Raeppel, Franck (Montreal, CA); Gaudette, Frederic ... [Published NewsRX - Jun 15 2013]

Entities: Tyrosine, Patent Issued, Kinase

First reported Jun 15 2013 - Updated Jun 15 2013 - 1 reports

Expression of ST3GAL4 Leads to SLex Expression and Induces c-Met Activation and an Invasive Phenotype in Gastric Carcinoma Cells

by Catarina Gomes, Hugo Osório, Marta Teixeira Pinto, Diana Campos, Maria José Oliveira, Celso A. ReisSialyl-Lewis X (SLex) is a sialylated glycan antigen expressed on the cell surface during malignant cell transformation and is associated with cancer ... [Published Elites TV - Jun 15 2013]

Entities: Phenotype, carcinoma, Antigen, Src

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

A Loss-of-Function Screen for Phosphatases that Regulate Neurite Outgrowth Identifies PTPN12 as a Negative Regulator of TrkB Tyrosine Phosphorylation

by Malene Ambjørn, Véronique Dubreuil, Federico Miozzo, Fabienne Nigon, Bente Møller, Shohreh Issazadeh-Navikas, Jacob Berg, Michael Lees, Jan SapAlterations in function of the neurotrophin BDNF are associated with neurodegeneration, cognitive decline, ... [Published Elites TV - Jun 14 2013]

Entities: Phosphatase, Tyrosine, Phosphorylation

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

/PRNewswire/ --Dr Wyndham Wilson will give an update on recent developments in the treatment of lymphomas with small molecules.The last 30 years have seen a plethora of treatments for diffuse large B-cell lymphoma (DLBCL) but few advances have been made. ... [Published Sys-Con Belgium - Jun 14 2013]

Entities: Ibrutinib, Lymphomas, Receptor

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Probing the Recognition of Post-Translational Modifications by Combining Sortase-Mediated Ligation and Phage-Assisted Selection

Reversible post-translational modifications (PTMs) are key regulators of protein function and modulate a multitude of protein–protein interactions in signal transduction networks. Here, we describe a strategy for determining the modification preferences ... [Published ACS Chemical Biology - Jun 13 2013]

Entities: Protein, ligation, Interaction

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Chronic Myeloid Leukemia Patients On Kinase Inhibitors Report Serious Quality-Of-Life Issues

chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include ... [Published Big News Network - Jun 12 2013]

Entities: Kinase, chronic myeloid leukemia, Patient, Tyrosine, Chemotherapy

First reported Jun 10 2013 - Updated Jun 11 2013 - 4 reports

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

nausea and change of appearance. The researchers say it is important to improve the patients' quality of life because most will take tyrosine kinase inhibitors for the rest of their lives. Their study appeared in the April issue of Supportive Care in ... [Published Big News Network - Jun 11 2013]

Entities: Tyrosine, Kinase, chronic myeloid leukemia

First reported Jun 03 2013 - Updated Jun 03 2013 - 2 reports

BerGenBio AS Presents Promising Therapeutic Candidate in AML at American Society of Clinical Oncology

Staying up-to-date has never been simpler. Sign up for the today! BerGenBio AS, an emerging oncology biopharma company, has presented data on the importance of the receptor tyrosine kinase, Axl, in acute myeloid leukemia (AML) at the ASCO Annual Meeting ... [Published BioSpace - Jun 03 2013]

Entities: American Society of Clinical Oncology, Acute Myeloid Leukemia, Tyrosine, Kinase

Quotes

"Lyn overexpression might be indispensable for cancer cells that rely on EGFR signaling to proliferate" Hung noted...

Scientists catch EGFR passing a crucial message to cancer-promoting protein [Published EurekAlert! - 13 hours ago]

"But if innovation cannot be ordained," responded Derek Lowe in his In The Pipeline blog, "why does a company need lots of people in high positions to ordain it, each with his or her own weekly meeting and online presentations database for all the PowerPoint slides? It's a head-scratcher of a problem, isn't it?"

Analysis: Big Pharma R&D demonstrates a woeful lack of innovation [Published FierceBiotech - 17 hours ago]

...Valerie Gouon-Evans, assistant professorprofessor of developmental and regenerative biology at the . "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem."

Cell Surface Receptor Guides Liver Development [Published Biotech Daily - 18 hours ago]

...Professor in the Department of Medicine at the UCLA Medical Center, Los Angeles, U S A , who presented the results at the EHA Congress today. "Given that patients with the ABC-subtype of DLBCL are difficult to treat, these results are very promising."

Pharmacyclics announces result of two phase II ibrutinib studies in patients with MCL or DLBCL [Published PharmaBiz - Jun 18 2013]

More Content

sort by: Date \| Relevance
GDNF–RET Signaling in ER-Positive Breast Cancer... [Published Bionity.com - 1 hour ago]
Targeting ROR1 Inhibits Epithelial–Mesenchymal ... [Published Bionity.com - 1 hour ago]
DOG1 Regulates Growth and IGFBP5 in Gastrointes... [Published Bionity.com - 1 hour ago]
Scientists catch EGFR passing a crucial message... [Published EurekAlert! - 13 hours ago]
Breast Actives Reviews - All Hype or Does It Re... [Published SBWire - 15 hours ago]
Crizotinib Improves Progression-Free Survival i... [Published National Cancer Institute - 15 hours ago]
Analysis: Big Pharma R&D demonstrates a woeful ... [Published FierceBiotech - 17 hours ago]
Cell Surface Receptor Guides Liver Development [Published Biotech Daily - 18 hours ago]
Bernard Munos on The Last Twelve Years of Pharma [Published Corante - 19 hours ago]
Pharmacyclics announces result of two phase II ... [Published PharmaBiz - Jun 18 2013]
Development of a Spontaneous Liver Disease Rese... [Published Elites TV - Jun 18 2013]
Taking a birth control pill? It might be leachi... [Published Metronews - Jun 18 2013]
Clinical Possibilities of Metal–Peptide Complexes [Published Drug Discovery and Development - Jun 18 2013]
Can Avastin’s Shortcomings Open the Door for De... [Published Proactive Investors USA - Jun 17 2013]
Group Of Experts Looks At High Price Of Cancer ... [Published Intellectual Property Watch - Jun 17 2013]
What’s Better: 5-Hour Energy or Coffee? [Published Men's Health US - Jun 17 2013]
Drug Delivery in Cancer - Technologies, Markets... [Published Bio-Medicine - Jun 17 2013]
Role of Slit and Robo Proteins in the Developme... [Published Sexual Development - Jun 17 2013]
Exelixis Initiates Phase 3 Pivotal Trial of Cab... [Published Pharmacy Choice - Jun 17 2013]
Addition of bevacizumab to initial treatment fo... [Published Pharmacy Choice - Jun 17 2013]
Ibrutinib monotherapy shows efficacy in patient... [Published News-Medical.Net - Jun 17 2013]
Human lysosomal protein and methods of its use [Published PharmCast - Jun 16 2013]
Aveo Pharma Hanging By A Thread [Published Seeking Alpha - Jun 16 2013]
Updated Results of Two Phase 2 Ibrutinib Studie... [Published PR Newswire: General Business - Jun 16 2013]
Ibrutinib Phase 2 Data: Analyses Show Efficacy ... [Published PR Newswire: Financial Services - Jun 16 2013]
Novartis drug JakaviÂ® improved overall surviva... [Published Individual.com - Jun 16 2013]
Patent Issued for Selected Inhibitors of Protei... [Published NewsRX - Jun 15 2013]
Expression of ST3GAL4 Leads to SLex Expression ... [Published Elites TV - Jun 15 2013]
IL-2–inducible T-cell kinase modulates TH2-medi... [Published Journal of Allergy and Clinical Immunology - Jun 15 2013]
A Loss-of-Function Screen for Phosphatases that... [Published Elites TV - Jun 14 2013]

sort by: Date \| Relevance
Bernard Munos on The Last Twelve Years of Pharma [Published Corante - 19 hours ago] Bernard Munos (ex-Lilly, now consulting) is out with a paper reviewing the approved drugs from 2000 to 2012. What's the current state of the industry? Is the upturn in drug approvals over the last two years real, or an artifact? And is it enough to keep ...
AstraZeneca Hands Late-Stage RA Drug Back to Rigel [Published Pharma-Mag - Jun 04 2013] Topline data from final two Phase III trials show SYK improves ACR20 response rates AstraZeneca says it won’t proceed with regulatory filings for the late-stage rheumatoid arthritis (RA) drug fostamatinib, and the firm has passed its rights to the oral ...
Phase 2 Study Results for Tivantinib in Combina... [Published EquityJungle - v0.1 - Jun 01 2013] Filed under: Investing Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer Presented at ASCO 2013 Signals of clinical benefit observed in consistent trends toward improved progression-free survival, ...
[Comment] Pre-eclampsia and the risk of kidney ... [Published The Lancet online - May 31 2013] Worldwide, about 2–8% of pregnancies are complicated by pre-eclampsia, a disorder that is characterised by new-onset hypertension and proteinuria after 20 weeks of pregnancy. Pre-eclampsia is associated with risk of adverse fetal outcomes and can progress ...
Cancer Treatments ‘Unaffordable’ and Will Drive... [Published Pharma-Mag - May 09 2013] The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and healthcare systems that does not necessarily correlate with the survival benefit the drug provides, and which is driving the rapid transition to generics ...